Equities Analysts Set Expectations for MBRX Q1 Earnings

Moleculin Biotech, Inc. (NASDAQ:MBRX) – HC Wainwright issued their Q1 2026 EPS estimates for Moleculin Biotech in a note issued to investors on Tuesday, March 24th. HC Wainwright analyst S. Nik anticipates that the company will post earnings of ($1.53) per share for the quarter. HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share. HC Wainwright also issued estimates for Moleculin Biotech’s Q2 2026 earnings at ($1.40) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($4.19) EPS and FY2027 earnings at ($3.60) EPS.

Several other brokerages also recently weighed in on MBRX. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a report on Thursday, January 22nd. Roth Mkm reaffirmed a “buy” rating on shares of Moleculin Biotech in a research report on Monday, December 15th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $22.00.

Moleculin Biotech Price Performance

Shares of MBRX stock opened at $2.43 on Thursday. The stock’s fifty day moving average price is $3.26 and its 200 day moving average price is $6.88. Moleculin Biotech has a 1-year low of $1.79 and a 1-year high of $28.61. The company has a market cap of $4.96 million, a price-to-earnings ratio of -0.07 and a beta of 1.73.

Institutional Investors Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC acquired a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech at the end of the most recent reporting period. 15.52% of the stock is owned by hedge funds and other institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.